Amneal Pharmaceuticals (AMRX) Earnings Analysis

Amneal Pharmaceuticals (AMRX) next reports earnings on 2026-07-30, consensus EPS 0.24 USD. Last quarter (2026-05-07) it beat with EPS 0.27 USD vs 0.17 USD est (+58.8%). It has beaten estimates in 6/7 recent quarters (86%). Trailing P/E 46.85.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does AMRX next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate0.24 USD
Revenue estimate0.77B

AMRX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-070.27 USD0.17 USD+58.8%Beat
2026-02-270.21 USD0.18 USD+16.7%Beat
2025-10-300.17 USD0.13 USD+30.8%Beat
2025-05-020.21 USD0.15 USD+40%Beat
2025-02-280.12 USD0.15 USD-20%Miss
2024-11-080.16 USD0.13 USD+23.1%Beat
2024-08-090.16 USD0.14 USD+14.3%Beat

Beat rate: 6/7 (86%) over reported quarters with consensus data.

AMRX valuation and analyst view

Trailing P/E46.85
Trailing EPS0.37199 USD
Price / book-128.57
Dividend yield0.00%
Market cap5.70B
Analyst consensusBuy (11 buy / 6 hold / 0 sell)
Avg price target19.5 USD

Related research pages

Frequently asked questions

When is Amneal Pharmaceuticals (AMRX)'s next earnings date?

Amneal Pharmaceuticals is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 0.24 USD and revenue estimate of 0.77B.

Did AMRX beat earnings last quarter?

In its 2026-05-07 report, AMRX posted EPS of 0.27 USD versus a 0.17 USD estimate — a beat of 58.8%.

What is AMRX's earnings track record?

Over the last 7 reported quarters with consensus data, AMRX beat estimates 6 times (86%).

What is AMRX's current P/E ratio and EPS?

AMRX trades at a trailing P/E of 46.85 on trailing EPS of 0.37198760841873574 USD.

What do analysts rate AMRX?

Analyst consensus is "Buy" across 17 ratings (0 strong buy, 11 buy, 6 hold, 0 sell, 0 strong sell). Average 12-month price target: 19.5 USD.